PCSK9: A key factor modulating atherosclerosis-Reference-Cited by-同舟云学术

PCSK9: A key factor modulating atherosclerosis

Published:2015 Issue:3 Volume:22 Page:221-230
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Li Sha¹,Li Jian-Jun¹

Affiliation:

1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Reference73 articles.

1. 1) Mendis S, Chestnov O: The global burden of cardiovascular diseases: a challenge to improve. Curr Cardiol Rep, 2014; 16: 486

2. 2) Wang JC, Bennett M: Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res, 2012; 111: 245-259

3. 3) van Diepen JA, Berbee JF, Havekes LM, Rensen PC: Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis, 2013; 228: 306-315

4. 4) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009

5. 5) Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis;Journal of Integrative Neuroscience;2024-03-20

2. Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling;Journal of Microbiology and Biotechnology;2022-09-23

3. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity;International Journal of Molecular Sciences;2022-08-29

4. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis;Antioxidants;2022-03-16

5. Therapeutic RNA-silencing oligonucleotides in metabolic diseases;Nature Reviews Drug Discovery;2022-02-24